|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||3.15 / 9.19|
The Dow is up more than 250 points.
The New Haven, Conn.-based firm on Sept. 9 received a termination notice regarding its license and collaboration pact with Johnson & Johnson's Janssen Pharmaceuticals Inc. on hepatitis C.
Thursday's downgrade is in part based on a lack of confidence in Achillion's CH-4471 to compete with Alexion Pharmaceuticals' Soliris treatment.
- Conference call and live webcast will begin at 4:05 p.m. ET on August 8, 2017 -
Investors in Achillion Pharmaceuticals Inc. saw new options begin trading today, for the March 2018 expiration.
Investors in Achillion Pharmaceuticals Inc. saw new options become available this week, for the July 21st expiration.
Robust balance sheet to support planned Phase 2 clinical development program for ACH-4471, Achillion's first small molecule factor D inhibitor, for the potential treatment of PNH and C3G
Investors in Achillion Pharmaceuticals Inc. saw new options begin trading this week, for the December 15th expiration.
Ongoing Janssen global Phase 2 program with JNJ-4178, (odalasvir, AL-335, and simeprevir) focused on treatment durations of six and eight weeks for HCV genotype 1, 2, 4, 5, and 6 patients
Here's how to potentially rake in some fat profits off a number of hot breakout setups.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AGNC, BBGI, BRID, IIJI, PERY Downgrades: ACHN, ALLY, FPO, FSS, SF, TTMI, VISI Initiations: TKAT Read on to get TheStreet Quant Ratings' detailed report:
Here's a technical look at how to trade several under-$10 stocks triggering breakout trades.
In trading on Friday, shares of Achillion Pharmaceuticals Inc. touched a new 52-week low of $3.75/share.
These four biotech stocks have been moving on some interesting news and clinical results.
Other movers include Incyte, Achillion and Inovio.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.